

PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY

MOBITOR INJECTION

ACTIVE CONSTITUENT 5mg/mL ATIPAMEZOLE

chloride in dogs and cats

For parenteral use in reversing and polishing the effects of mediatomiding ydrochloride and dexmediatomiding

10ml

MOBITO ACTIVE CONSTIT HYDROCHLORID

tomidine hydrochloride and dex de in doos and cats.

ing and ab

MOBITOR INJECTION

For parenteral use in reversing and abolishing the medetomidine hydrochloride effects of and dexmedetomidine hydrochloride in dogs and cats.

ACTIVE CONSTITUENT:

ATIPAMEZOLE HYDROCHLORIDE 5mg/mL

NET CONTENTS: 10mL

GENERAL DIRECTIONS

DOSAGE AND ADMINISTRATION

In-use shelf life: Discard the unused portion within 12

weeks of first broaching. This product is to be used by the intramuscular (IM) route of administration. The following dosage should be adhered to when administering to counter the effects of medetomidine hydrochloride (Stilator Injection):

HEADWA D

ANIMAL DOSE QUANTITY

Dog 5 times that of previous 1 mg/mL medetomidine hydrochloride dose (50-400 μ g/kg atipamezole hydrochloride). The same volume as the medetomidine hydrochloride dose.

Cat 2.5 times that of previous 1mg/mL medetomidine hydrochloride dose (125-375 μ g/kg atipamezole hydrochloride). Half the volume of the medetomidine hydrochloride dose.

The following dosage should be adhered to when administering Mobitor to counter the effects of dexmedetomidine hydrochloride:

ANIMAL DOSE QUANTITY

Dog 10 times that of previous 0.5mg/mL dexmedetomidine hydrochloride dose (375-500 µg/kg atipamezole hydrochloride). The same volume as the 0.5mg/mL dexmedetomidine hydrochloride dose.

Cat 5 times that of previous 0.5mg/mL dexmedetomidine hydrochloride dose (200 μ g/kg atipamezole hydrochloride).

Half the volume as the 0.5mg/mL dexmedetomidine hydrochloride dose. Mobitor is quickly absorbed and it is recommended that at these dose levels it can be administered 15 to 60 minutes after administration of medetomidine hydrochloride or dexmedetomidine hydrochloride dose.

The following dosage should be adhered to when administering Mobitor to counter the effects of medetomidine hydrochloride:



Animal	Dose	Quantity
Dog	5 times that of previous 1mg/mL medetomidine hydrochloride dose (50-400μg/kg atipamezole)	The same volume as the 1mg/mL medetomidine hydrochloride dose
Cat	2.5 times that of previous 1mg/mL medetomidine hydrochloride dose (125- 375µg/kg atipamezole)	Half the volume of the 1mg/mL medetomidine hydrochloride dose

The following dosage should be adhered to when administering Mobitor to counter the effects of dexmedetomidine hydrochloride:

Animal	Dose	Quantity
Dog	10 times that of previous 0.5mg/mL dexmedetomidine hydrochloride dose (3.75-5.00mg/m ² atipamezole)	The same volume as the 0.5mg/mL dexmedetomidine hydrochloride dose
Cat	5 times that of previous 0.5mg/mL dexmedetomidine hydrochloride dose (200µg/kg atipamezole)	Half the volume of the 0.5mg/mL dexmedetomidine hydrochloride dose

PRECAUTIONS

Due to the potent pharmacological activity of Atipamezole, skin contact with this product should be avoided. Wipe off excess spillage on skin of animals.

SIDE EFFECTS

In dogs, a transient hypotensive effect has been observed with Atipamezole HCl injections during the first 10 minutes post-injection. Vomiting and panting after Atipamezole injection have been reported, but these effects appear to be rare. Transient over-alertness and tachycardia may be observed after a possible overdosage.

CONTRAINDICATIONS

Atipamezole has only been administered to a limited number of pregnant dogs so cannot be recommended during pregnancy.

STORAGE

Store below 30°C (Room temperature). Do not freeze. Protect from light. APVMA Approval No.: 86194

Address: A9/20 Picrite Close, Pemulwuy, NSW-2145 Post Address: PO Box 465, Wentworthville, NSW-2145